Gankyrin as a potential target for tumor therapy: evidence and perspectives

American Journal of Translational Research

Junyan Zhang¹  Haixai Li² 

[1] Beijing 302 Hospital, Beijing 100039, China;Department of Obstetrics and Gynecology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China

关键词: Gankyrin;    target;    tumor therapy;   

DOI  :  

学科分类：医学（综合）

来源: e-Century Publishing Corporation

【 摘 要 】

Gankyrin (also known as PSMD10 or p28GANK), engages in diverse biological processes, including cellular growth, proliferation and invasion. Several studies have demonstrated that Gankyrin is a candidate oncogene. In parallel, the dysregulation of Gankyrin has been observered in a variety of human cancer. Overexpression of Gankyrin is involved in tumor initiation and progression by regulating several signaling pathways that control cell-cycle process, cell growth, apoptosis, et al. On the contrary, downregulation of Gankyrin significantly inhibits cell growth, proliferation and metastasis. Therefore, Gankyrin appears to be a potential target for tumor therapy. Herein, this review summarizes the current knowledge in understanding the biological functions and oncogenic role of Gankyrin in human cancers from the perspective of clinical-pathological significances, aiming to provide guidance for the development of Gankyrin-targeted therapy.

【 授权许可】

CC BY-NC